Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Olmesartan medoxomil
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ach-Olmesartan · DIN 02456311 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Olmesartan · DIN 02456311
Manufacturer: Accord Healthcare Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-05-06 · brand ACH-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456311)
Source record
DIN 02456311: Ach-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id ACH
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456311
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94319
Interchangeable products
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended March 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02456311
Shortage record checked October 6, 2026
Auro-Olmesartan · DIN 02443864 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Olmesartan · DIN 02443864
Manufacturer: Auro Pharma Inc.; listing date 2017-06-29
Health Canada: Marketed since 2017-05-01 · brand AURO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443864)
Source record
DIN 02443864: Auro-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443864
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92863
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended October 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443864
Shortage record checked October 6, 2026
GLN-Olmesartan · DIN 02469812 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
GLN-Olmesartan · DIN 02469812
Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2020-12-18
Health Canada: Marketed since 2019-03-05 · brand GLN-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGLN-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02469812)
Source record
DIN 02469812: GLN-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id GLP
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02469812
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95870
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended April 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469812
Shortage record checked October 6, 2026
Jamp-Olmesartan · DIN 02461641 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Olmesartan · DIN 02461641
Manufacturer: Jamp Pharma Corporation; listing date 2017-06-29
Health Canada: Marketed since 2021-10-28 · brand JAMP OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461641)
Source record
DIN 02461641: Jamp-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461641
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94931
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended March 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461641
Shortage record checked October 6, 2026
NRA-Olmesartan · DIN 02499258 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Olmesartan · DIN 02499258
Manufacturer: Nora Pharma; listing date 2020-12-18
Health Canada: Marketed since 2020-11-04 · brand NRA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02499258)
Source record
DIN 02499258: NRA-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id NRA
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02499258
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98899
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended May 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02499258
Shortage record checked October 6, 2026
Olmesartan · DIN 02481057 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Olmesartan · DIN 02481057
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2020-02-21 · brand OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordOlmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02481057)
Source record
DIN 02481057: Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02481057
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97140
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02481057
Shortage record checked October 6, 2026
Olmetec · DIN 02318660 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
1 brand, same coverage
Olmetec · DIN 02318660
Manufacturer: Organon Canada Inc.; listing date 2010-04-23
Health Canada: Marketed since 2023-08-03 · brand OLMETEC · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02318660)
Source record
DIN 02318660: Olmetec
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id OCI
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.3993; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02318660
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80414
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended August 1, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02318660
Shortage record checked October 6, 2026
PMS-Olmesartan · DIN 02461307 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Olmesartan · DIN 02461307
Manufacturer: Pharmascience Inc.; listing date 2017-07-31
Health Canada: Marketed since 2017-06-02 · brand PMS-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461307)
Source record
DIN 02461307: PMS-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id PMS
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461307
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94881
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: discontinued (November 15, 2021, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461307
Shortage record checked October 6, 2026
Sandoz Olmesartan · DIN 02443414 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Olmesartan · DIN 02443414
Manufacturer: Sandoz Canada Inc.; listing date 2017-06-29
Health Canada: Marketed since 2017-05-01 · brand SANDOZ OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443414)
Source record
DIN 02443414: Sandoz Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id SDZ
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443414
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92810
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: resolved shortage (ended April 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443414
Shortage record checked October 6, 2026
Teva-Olmesartan · DIN 02442191 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Olmesartan · DIN 02442191
Manufacturer: Teva Canada Limited; listing date 2017-06-29
Health Canada: Marketed since 2023-03-10 · brand TEVA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442191)
Source record
DIN 02442191: Teva-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id TEV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442191
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92655
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Apo-Olmesartan · DIN 02453452 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442191
Shortage record checked October 6, 2026
Ach-Olmesartan · DIN 02456338 · 40 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Olmesartan · DIN 02456338
Manufacturer: Accord Healthcare Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-05-06 · brand ACH-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456338)
Source record
DIN 02456338: Ach-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id ACH
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456338
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94320
Interchangeable products
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended May 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02456338
Shortage record checked October 6, 2026
Auro-Olmesartan · DIN 02443872 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Olmesartan · DIN 02443872
Manufacturer: Auro Pharma Inc.; listing date 2017-06-29
Health Canada: Marketed since 2017-05-01 · brand AURO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443872)
Source record
DIN 02443872: Auro-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id AUR
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443872
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92864
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: discontinued (November 21, 2023, reported by AURO PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443872
Shortage record checked October 6, 2026
GLN-Olmesartan · DIN 02469820 · 40 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
GLN-Olmesartan · DIN 02469820
Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2020-12-18
Health Canada: Marketed since 2019-03-05 · brand GLN-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGLN-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02469820)
Source record
DIN 02469820: GLN-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id GLP
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02469820
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95871
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended July 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469820
Shortage record checked October 6, 2026
Jamp-Olmesartan · DIN 02461668 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Olmesartan · DIN 02461668
Manufacturer: Jamp Pharma Corporation; listing date 2017-06-29
Health Canada: Marketed since 2021-10-28 · brand JAMP OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461668)
Source record
DIN 02461668: Jamp-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id JPC
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461668
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94932
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended March 7, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461668
Shortage record checked October 6, 2026
NRA-Olmesartan · DIN 02499266 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Olmesartan · DIN 02499266
Manufacturer: Nora Pharma; listing date 2020-12-18
Health Canada: Marketed since 2020-11-04 · brand NRA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02499266)
Source record
DIN 02499266: NRA-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id NRA
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02499266
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98900
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended May 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02499266
Shortage record checked October 6, 2026
Olmesartan · DIN 02481065 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Olmesartan · DIN 02481065
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2020-02-21 · brand OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordOlmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02481065)
Source record
DIN 02481065: Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id SAI
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02481065
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97141
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended November 26, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02481065
Shortage record checked October 6, 2026
Olmetec · DIN 02318679 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
1 brand, same coverage
Olmetec · DIN 02318679
Manufacturer: Organon Canada Inc.; listing date 2010-04-23
Health Canada: Marketed since 2023-04-13 · brand OLMETEC · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02318679)
Source record
DIN 02318679: Olmetec
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id OCI
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.3993; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02318679
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80415
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended September 17, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02318679
Shortage record checked October 6, 2026
PMS-Olmesartan · DIN 02461315 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Olmesartan · DIN 02461315
Manufacturer: Pharmascience Inc.; listing date 2017-07-31
Health Canada: Marketed since 2017-06-02 · brand PMS-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461315)
Source record
DIN 02461315: PMS-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id PMS
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461315
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94882
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended April 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461315
Shortage record checked October 6, 2026
Sandoz Olmesartan · DIN 02443422 · 40 mg · tablet
General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Olmesartan · DIN 02443422
Manufacturer: Sandoz Canada Inc.; listing date 2017-06-29
Health Canada: Marketed since 2017-05-01 · brand SANDOZ OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443422)
Source record
DIN 02443422: Sandoz Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id SDZ
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443422
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92811
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: resolved shortage (ended May 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443422
Shortage record checked October 6, 2026
Teva-Olmesartan · DIN 02442205 · 40 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Olmesartan · DIN 02442205
Manufacturer: Teva Canada Limited; listing date 2017-06-29
Health Canada: Marketed since 2023-03-10 · brand TEVA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442205)
Source record
DIN 02442205: Teva-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id TEV
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442205
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92656
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Apo-Olmesartan · DIN 02453460 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442205
Shortage record checked October 6, 2026
Apo-Olmesartan · DIN 02453452 · 20 mg · tablet
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Olmesartan · DIN 02453452
Manufacturer: Apotex Inc.; listing date 2017-06-29
Health Canada: Dormant since 2025-05-16 · brand APO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02453452)
Source record
DIN 02453452: Apo-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453452
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94000
Interchangeable products
Ach-Olmesartan · DIN 02456311 · $0.3019
Auro-Olmesartan · DIN 02443864 · $0.3019
GLN-Olmesartan · DIN 02469812 · $0.3019
Jamp-Olmesartan · DIN 02461641 · $0.3019
NRA-Olmesartan · DIN 02499258 · $0.3019
Olmesartan · DIN 02481057 · $0.3019
Olmetec · DIN 02318660 · $0.3019
PMS-Olmesartan · DIN 02461307 · $0.3019
Sandoz Olmesartan · DIN 02443414 · $0.3019
Teva-Olmesartan · DIN 02442191 · $0.3019
Shortage status: active shortage (reported May 7, 2024, last updated May 10, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453452
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since May 16, 2025 — choose a marketed DIN from the same-category list.
Apo-Olmesartan · DIN 02453460 · 40 mg · tablet
General benefitDormant since November 7, 2025 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Olmesartan · DIN 02453460
Manufacturer: Apotex Inc.; listing date 2017-06-29
Health Canada: Dormant since 2025-11-07 · brand APO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Olmesartan: Formulary list price $0.30 per unit (the source does not state the unit; exact figure $0.3019). What the ministry pays, not the patient.
Ministry pays: $0.3019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02453460)
Source record
DIN 02453460: Apo-Olmesartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id APX
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3019; ministry $0.3019
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453460
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94001
Interchangeable products
Ach-Olmesartan · DIN 02456338 · $0.3019
Auro-Olmesartan · DIN 02443872 · $0.3019
GLN-Olmesartan · DIN 02469820 · $0.3019
Jamp-Olmesartan · DIN 02461668 · $0.3019
NRA-Olmesartan · DIN 02499266 · $0.3019
Olmesartan · DIN 02481065 · $0.3019
Olmetec · DIN 02318679 · $0.3019
PMS-Olmesartan · DIN 02461315 · $0.3019
Sandoz Olmesartan · DIN 02443422 · $0.3019
Teva-Olmesartan · DIN 02442205 · $0.3019
Shortage status: active shortage (reported November 12, 2024, last updated November 14, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453460
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since November 7, 2025 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (C09CA): coverage varies; not interchangeable
- Candesartan cilexetil (Atacand): general benefit
- Irbesartan (Avapro): general benefit, not a benefit
- Losartan (Cozaar): general benefit
- Telmisartan (Micardis): general benefit
- Valsartan (Diovan): general benefit, not a benefit
- Eprosartan (Teveten): general benefit
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 41 products · Listed, not a benefit (1), General benefit (40) · strengths: 75mg, 150mg, 300mg · Tab
· 42 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab
· 25 products · General benefit · strengths: 40mg, 80mg · Tab
· 38 products · Off-Formulary Interchangeable, not an ODB benefit (10), General benefit (28) · strengths: 40mg, 80mg, 160mg, 320mg · Tab
· 2 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 400mg, 600mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 2 products · General benefit · strengths: 5mg/12.5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08
and 34 more
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monograph
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46)
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monograph
BENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for:
• the treatment of essential hypertension in patients for whom combination therapy is
appropriate.
PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10
Product monograph
CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monograph
CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monograph
CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monograph
ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:
Treatment of essential hypertension in patients for whom this combination therapy with
enalapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10
Product monograph
and 19 more
Coverage source: ON formulary extract 2026-09-22
Availability
PMS-Olmesartan · DIN 02461307
Shortage status: discontinued (2021-11-15, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461307
Check this DIN againTeva-Olmesartan · DIN 02442191
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442191
Check this DIN againAuro-Olmesartan · DIN 02443872
Shortage status: discontinued (2023-11-21, reported by AURO PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443872
Check this DIN againTeva-Olmesartan · DIN 02442205
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442205
Check this DIN againApo-Olmesartan · DIN 02453452
Shortage status: active shortage (reported 2024-05-07, last updated 2024-05-10) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453452
Check this DIN againApo-Olmesartan · DIN 02453460
Shortage status: active shortage (reported 2024-11-12, last updated 2024-11-14) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453460
Check this DIN againAct Olmesartan HCT · DIN 02443112
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443112
Check this DIN again